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Objectives This study aimed at examining the efficacy of bone marrow mononuclear cell (BMMNC) delivery through graft vessel
for patients with a previous myocardial infarction (MI) and chronic heart failure during coronary artery bypass graft
(CABG).
Background Little evidence exists supporting the practice of BMMNC delivery through graft vessel for patients with a previous
MI and chronic heart failure during CABG.
Methods From November 2006 to June 2009, a randomized, placebo-controlled trial was conducted to test the efficacy and
safety of CABG for multivessel coronary artery disease combined with autologous BMMNCs in patients with conges-
tive heart failure due to severe ischemic cardiomyopathy. Sixty-five patients were recruited, and 60 patients remained
in the final trial and were randomized to a CABG  BMMNC group (n  31) and a placebo-control group (i.e., CABG-
only group, n 29). All patients discharged received a 6-month follow-up. Changes in left ventricular ejection fraction
from baseline to 6-month follow-up, as examined by magnetic resonance imaging, were of primary interest.
Results The overall baseline age was 59.5  9.2 years, and 6.7% were women. After a 6-month follow-up, compared
with the placebo-control group, the CABG  BMMNC group had significant changes in left ventricular ejection
fraction (p  0.029), left ventricular end-systolic volume index (p  0.017), and wall motion index score
(p  0.011). Also, the changes in the distance on the 6-min walking test as well as B-type natriuretic peptide
were significantly greater in the CABG  BMMNC group than in the control group.
Conclusions In summary, patients with a previous MI and chronic heart failure could potentially benefit from isolated CABG (i.e.,
those who received CABG only) combined with BMMNCs delivered through a graft vessel. (Stem Cell Therapy to Im-
prove Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting [CABG]; NCT00395811) (J Am
Coll Cardiol 2011;57:2409–15) © 2011 by the American College of Cardiology Foundation
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Stem Cells in Post-Infarction Heart Failure June 14, 2011:2409–15There is well-established evi-
dence of the benefit of revascu-
larization for reviving stunned or
hibernating myocardium in pa-
tients with ischemic heart disease
(1). However, the ventricular re-
modeling process is generally ir-
reversible, especially in patients
with end-stage ischemic cardiomy-
opathy (1). Cell transplantation, as
represented by bone marrow–
derived cell transplantation, gives
rise to a new therapeutic method
for patients with ischemic cardio-
myopathy (2). A number of ran-
domized trials have shown that in
patients with acute myocardial in-
farction (MI), stem cell trans-
plantation through various ways
will improve the left ventricular
ejection fraction (LVEF) and re-
verse, to a certain extent, ventric-
ular remodeling (3–5). Despite
the promising results, the evidence
regarding the therapeutic effect of
cell transplantation in patients
with a previous MI (PMI) and heart failure is still lacking (6,7).
Our previous observational studies have shown that a coronary
artery bypass graft (CABG) combined with autologous bone
marrow mononuclear cells (BMMNCs) appeared to be feasi-
ble and safe for this group of patients (8). To establish further
the efficacy and safety of CABGBMMNCs in patients with
PMI and heart failure, we conducted a randomized trial
involving 60 patients recruited in a single center.
Methods
This study was a randomized, placebo-controlled trial of the
efficacy and safety of a CABG combined with autologous
BMMNCs in patients presenting with congestive heart
failure due to severe ischemic cardiomyopathy.
Patient population. The recruitment took place between
November 2006 and June 2009. Patients of ages 18 to 75
years with congestive heart failure and suitable for elective
CABG surgery were considered for the study. Patients were
eligible if they had met all the following conditions: 1) at
least 3 months since the last MI; 2) planned CABG for
triple-vessel disease and according to American Heart
Association guidelines (Indications for CABG in Poor LV
Function) (9); 3) no evidence of surviving myocardium in
the infarct area, as shown by single-photon emission com-
puted tomography (SPECT) and left ventricular angiogra-
phy; 4) LVEF 30% on magnetic resonance imaging; and
5) without left ventricular (LV) aneurysm or valvular dis-
eases requiring surgical intervention. Patients were not
Abbreviations
and Acronyms
BMMNC  bone marrow
mononuclear cell
BNP  B-type natriuretic
peptide
CABG  coronary artery
bypass graft
LV  left ventricular
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVESVI  left ventricular
end-systolic volume index
MI  myocardial infarction
MRI  magnetic resonance
imaging
6MWT  6-min walking
test
PMI  previous myocardial
infarction
SPECT  single-photon
emission computed
tomographyeligible if they had any one of the following conditions: 1)mitral regurgitation, LV aneurysm, or intraventricular
thrombus requiring concurrent surgery by transesophageal
echocardiography during operation; 2) contraindications to
cardiac magnetic resonance imaging (MRI); 3) significant
ventricular arrhythmias (sustained ventricular tachycardia)
or atrial fibrillation; 4) primary hematologic diseases; 5)
history of neoplasia or malignancy potentially influencing
the patient’s survival; 6) unexplained abnormality at labora-
tory baseline value; 7) history of other severe chronic
diseases; and 8) unwillingness to participate. All participants
gave written informed consent at enrollment and received
the same treatment and rehabilitation regimens as the
standard CABG protocol.
Procedures. Patients were randomly assigned to the stem
cell group or placebo-control group in a 1:1 ratio. In the
current study, the placebo-control group refers to the
CABG-alone group. The random table was generated by
the SAS software version 9.13 (SAS Institute, Cary, North
Carolina). After randomization, the study processes were
blinded to the patients, participating surgeons, coordinators,
and investigators who were responsible for patient assess-
ment were blinded to the study processes. The study was
approved by the ethics committee of Fuwai Hospital,
Peking Union Medical College. The study protocol is
shown in Figure 1.
Baseline data were collected pre-operatively, and outcomes
such as all-cause death, MI, revascularization, and congestive
heart failure were documented post-operatively. At 6 months
after surgery, all patients underwent cardiac MRI, SPECT,
and echocardiography assessment as well as a 6-min walking
test (6MWT), and BNP value. The 24-h Holter electrocar-
Figure 1 Trial Profile
Of the 65 patients who provided written consent, 60 patients entered the cur-
rent study. Then, they were randomized into CABGBMMNC group and control
group. A 6-month follow-up session was carried out in all the 60 patients.
BMMNC  bone marrow mononuclear cell; BNP  B-type natriuretic peptide;
CABG  coronary artery bypass graft; CHF  congestive heart failure; MI 
myocardial infarction; MRI  magnetic resonance imaging; SPECT  single-
photon emission computed tomography; 3D ECHO  3-dimensional echocardi-
ography; 6MWT  6-min walking test.
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June 14, 2011:2409–15 Stem Cells in Post-Infarction Heart Failurediogram was performed to monitor the occurrence of arrhyth-
mias for all patients during all the trial sessions.
Preparation and transplantation of BMMNCs. On the
day of the CABG procedure, BMMNCs were harvested
from each patient in the operating room and processed in
the Key Laboratory for Cardiovascular Regenerative Med-
icine, the Ministry of Health. After anesthesia but before
CABG, 60 ml of bone marrow was aspirated from the
patient’s iliac crest by an experienced hematologist and
diluted with normal saline solution. The mononuclear cells
were isolated using Ficoll (Amersham Biosciences, Piscat-
away, New Jersey) density gradient centrifugation according
to good manufacturing practice regulations, and resus-
pended in 10 ml of saline solution. The cell suspension was
filtered by a 70-m cell strainer (Gibco, Grand Island, New
York) before transplantation. The cells were counted under a
light microscope, and the viability was assessed by trypan blue
dye. The final suspension of BMMNCs contained 107/ml
mononuclear cells. The placebo solution was a mixture of 8 ml
of saline solution and 2 ml of the patient’s own serum. After
randomization, a syringe containing either bone marrow cell
suspension or placebo solution was brought to the operating
room.
All surgeries were performed by 2 senior surgeons, with
the same anesthetists and perfusionists. Standard techniques
were adopted by cardiopulmonary bypass, using cold ante-
grade cardioplegia, and moderate systemic hypothermia
(28°C to 32°C). A left internal mammary artery graft was
Figure 2 Solution Injected via the Saphenous Vein Bypass Graf
Illustration of the intraoperative cell delivery method via the right coronary artery (A
(D) A sketch of the stem cell injection procedure.anastomosed to the left anterior descending artery, and
saphenous vein was used for other target vessels. The
blinded cell or placebo solution was injected via the saphe-
nous vein bypass graft after distal anastomosis of the right
coronary artery and left circumflex coronary artery. Each
saphenous vein bypass graft area received 3 ml of solution,
and 4 ml of solution was injected through distal left anterior
descending artery anastomosis right before completion of
distal left anterior descending artery bypass graft (Fig. 2).
Outcome measures. The primary endpoint for assessment
of the efficacy was the changes in the LVEF from baseline to
6-month follow-up, assessed using MRI. Secondary efficacy
endpoints were LV end-diastolic volume index by MRI, left
ventricular end-systolic volume index (LVESVI) by MRI, wall
motion index score by 3-dimensional echocardiography, per-
fusion score by SPECT, 6MWT, and BNP value.
During the current study, an independent data safety
monitoring board met on a regular basis to review the
efficacy and safety of the data, which included: 1) major
cardiac adverse events, defined as the composite of all-cause
death, resuscitated sudden death, MI, and congestive heart
failure; and 2) arrhythmias as detected by 24-h Holter
monitoring, with main categories including sustained ven-
tricular fibrillation or polymorphic ventricular tachycardia,
sustained monomorphic ventricular tachycardia at a rate
120 beats/min, wide-complex tachycardia of unclear type,
sustained atrial fibrillation or flutter, bradyarrhythmia and
r Distal Anastomosis
left circumflex artery (B), and the left anterior descending artery (C).t Afte
), the
e
t
s
V
E
m
d
M
m
m
d
a
(
m
o
e
S
d
M
n
p
M
t
C
f
t
i
o
d
c
S
c
s
L
e
2412 Hu et al. JACC Vol. 57, No. 24, 2011
Stem Cells in Post-Infarction Heart Failure June 14, 2011:2409–15shock delivered by an implantable cardioverter-defibrillator,
bradyarrhythmia pacing, or antitachycardia pacing.
Cardiac MRI. Cardiac MRI was performed using a 1.5-T
scanner (Siemens Medical, Erlangen, Germany) with a
surface body coil, electrocardiography gating, and respira-
tory triggering. Sequence parameters were as follows: bal-
anced fast field echo gradient echo sequence with dynamic
sequences in transversal plane; long-axis, short-axis, and
4-chamber views; and 3-dimensional T1-weighted fast field
echo gradient echo sequence with multishot and TFE
prepulse with variable delay between 200 and 300 ms after
intravenous contrast injection of Magnevist (Bayer Schering
Pharma, Morristown, New Jersey). Global parameters as-
sessed include LVEF, LVEDV index (LVEDV index 
LVEDV  body surface area), and LVESVI (LVESVI 
LVESV  body surface area). Endocardial and epicardial
borders were traced in all end-diastolic and end-systolic
short axis and long axis slices to determine LVEDV and
LVESV for calculation of global LVEF, with ejection
fraction  ([LVEDV  LVESV]/LVEDV)  100%. Two
xperienced observers blinded to all clinical data analyzed
he images.
All MRI was quantitatively analyzed by commercial
oftware provided by Siemens (Syngo VD10B, Syngo
X49B, Argus VA60C).
chocardiography. Regional myocardial contractility was
easured by real-time transthoracic 3-dimensional echocar-
iography using a Philips IE33 ultrasound system (Philips
edical Systems, Irvine, California). Regional LV wall
otion analysis was performed as described by the Com-
ittee on Standards of the American Society of Echocar-
iography, by dividing the left ventricle into 16 segments
nd scoring wall motion for each segment as 1 (normal), 2
Baseline CharacteristicsTable 1 Baseline Characteristics
CABG  BMMNC Gro
Age, yrs 56.61 9.7
NYHA functional class 3 (2, 3)
CCS class 1 (2, 3)
No. of grafts 4 (4.0, 4.5
CPB time, min 91 (79, 10
Clamping time, min 59 (47, 68
Ventilation time, h 16 (13.5, 1
ICU stay, days 3 (4.0, 5.
MRI LVEDVI, ml/m2 106.20 (90.10, 1
MRI LVESVI, ml/m2 80.13 (67.18, 1
MRI LVEF 22.78 (19.76, 2
Echo segment movement score 39 (36, 41
Ratio of borderline MI, % 18.95 3.9
Ratio of complete MI, % 33.99 12
6-min walking test 466 (402, 4
BNP 1,329 (704, 1
Values are mean  SD or median (quartile).
BNP  B-type natriuretic peptide; BMMNC  bone marrow mo
Cardiovascular Society; CPB cardiopulmonary bypass; ICU intensi
ventricular ejection fraction; LVESVI  left ventricular end-systolic volume ind
NYHA  New York Heart Association.hypokinesis), 3 (akinesis), or 4 (dyskinesis). The wall
otion index score was calculated as the sum of the scores
f the segments divided by the number of segments
valuated.
ingle-photon emission computed tomography. Myocar-
ial perfusion imaging was performed by gated SPECT (Siemens
edical) 90 min after technetium-99m sestamibi was intrave-
ously injected. Myocardial 18F-fluorodeoxyglucose imaging was
erformed by SPECT with an ultra-high energy collimator.
yocardial perfusion was analyzed using Cedar-Sinai Quantita-
ive Perfusion SPECT software (Cedars-Sinai, Los Angeles,
alifornia). To assess the improvement in myocardial per-
usion and viability after intervention, relative segment of
echnetium-99m sestamibi and 18F-fluorodeoxyglucose up-
take were calculated as a percentage of uptake of the
segment with maximal uptake (normalization to the 100%
perfusion maximum). The left ventricle was divided into 17
segments according to the American Heart Association/
American College of Cardiology recommendations, and image
analysis was performed using semiquantitative analysis. The
segmental tracer activity was categorized on a 4-point scale: 1
denoting tracer activity of 75%; 2 denoting tracer activity of
50% to 75%; 3 denoting tracer activity of 25% to 49%; and 4
denoting tracer activity of 25%. Perfusion defects on stress
mages were considered present when tracer activity was75%
f maximum. When significant fill-in (10%) of perfusion
efects was observed on the resting images, segments were
lassified as ischemic.
tatistical analysis. Sample size estimation was based on a
linically relevant increase in LVEF of at least 5%. A
tandard error of 2% was expected at each assessment of the
VEF (the standard error of the mean of 3 baseline studies
stimated to 1%). Given these assumptions to detect a true
 31) Placebo-Control Group (n  29) p Value
58.27 8.86 0.501
2 (2, 3) 0.469
2 (2, 3) 0.101
4 (4.0, 4.5) 0.537
89 (80, 116) 0.299
53 (47, 73) 0.975
17 (15, 20) 0.358
3 (3, 4) 0.257
) 93.33 (83.35, 111.13) 0.116
) 71.51 (62.61, 84.11) 0.140
24.95 (20.72, 29.15) 0.287
38 (36, 40) 0.460
24.60 11.71 0.185
28.88 11.60 0.355
448 (383, 497) 0.272
862 (680, 1,646) 0.439
ear cell; CABG  coronary artery bypass graft; CCS  Canadian
unit; LVEDVI left ventricular end-diastolic volume index; LVEF leftup (n
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June 14, 2011:2409–15 Stem Cells in Post-Infarction Heart Failureincrease in the LVEF of 6% with an SD of 8% and a power
of 80%, a sample size of 52 patients was required.
Continuous variables are presented as mean SD, unless
therwise specified. Categorical variables were compared
etween the 2 treatment groups using the chi-square test or
isher exact test. Statistical comparisons between the initial
nd follow-up data were performed in a nonparametric,
aired fashion using Wilcoxon signed-rank test. Nonpara-
etric Mann-Whitney U tests and Kruskal-Wallis tests
ere used to compare continuous variables with categorical
ariables as well as to compare the results between treatment
roups. All the statistical analyses were performed using
AS version 9.13 (SAS Institute).
esults
aseline characteristics. From November 2006 to June
009, 65 patients were evaluated for eligibility and 5
atients were excluded because they had to undergo con-
omitant mitral valve repair or ventricular aneurysmectomy.
f the 60 patients randomized (31 in the CABG 
MMNC group and 29 in the placebo-control group),
here was a good balance between the 2 groups with respect
o baseline characteristics (Table 1). Mean  SD age was
9.5  9.2 years, and 6.7% were women (n  4). The heart
unction classification of the New York Heart Association
veraged 2.5  0.6, and 43 patients had a history of heart
ailure. Seven patients had a history of malignant arrhyth-
ia (ventricular tachycardia or fibrillation) and were suc-
essfully converted electrically. The LVEF examined by
RI ranged from 13% to 29% and averaged 0.23  0.6.
he SPECT perfusion imaging showed a ratio of borderline
I of 22.06  9.03% and a ratio of complete MI of 31.18
11.93%.
he harvested BMMNCs. The number of harvested
MMNCs ranged from 1.08 to 70  107 with an average
of 13.17  10.66  107. The ratio of viable BMMNCs was
98%. The BMMNCs have proliferative potential in vitro.
he primary cell formed a clone at approximately 10 days,
nd the time from primary passage to the first passage was
2 to 14 days. Microbiological examination showed no
ontamination of the culture.
ntraoperative and early post-operative outcomes. Of
he 60 patients enrolled, the number of grafts was 4  0.7
range 3 to 5 grafts) and the cardiopulmonary bypass time
as 90 18 min (range 61 to 154 min). Nine patients were
ssisted by intra-aortic balloon pump because of post-
perative pulmonary capillary wedge pressure 20 mm Hg,
nd all were weaned successfully from the intra-aortic
alloon pump at 1 to 3 days after surgery and discharged.
ne patient received an LV assist device (BVS5000,
biomed, Danvers, Massachusetts) and weaned 7 days
ater. The ventilation time was 22 36 h (range 7 to 168 h)
nd the length of intensive care unit stay was 5  1 days
range 1 to 36 days). Two patients had neurological com- Ch T
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r
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Stem Cells in Post-Infarction Heart Failure June 14, 2011:2409–15plications but recovered and were discharged. No patients
had arrhythmia, as defined previously.
Follow-up outcomes. After surgery, all patients except 1 in
the placebo-control group attended a 6-month follow-up
visit. Cardiac MRI revealed more significant improvement
in the LVEF (change  post-operative value – pre-
perative value) in the CABG  BMMNC group than in
the placebo-control group (Table 2). As for echocardio-
graphic examination, the changes in the 17-segment wall
motion score and the score of segments with abnormal
motion were significantly better in the CABG BMMNC
group than in the placebo-control group (Table 3). In the
CABG  BMMNC group, the perfusion score decreased
significantly, although the difference in the changes in
perfusion score did not reach significance level between the
2 groups (Table 4).
Two patients did not take the 6MWT, and 1 patient died
during follow-up, leaving 56 patients with available data on
the 6MWT. The distance increased more significantly in
the CABG  BMMNC group than in the placebo-control
group (Table 5). Also, the change in BNP was more
significant in the CABG  BMMNC group than in the
placebo-control group (Table 6). As for the safety issue, no
deaths or MI occurred during follow-up, nor was there any
report of arrhythmia during the post-operative period. The
proportion of patients who had experienced heart failure did
not differ significantly between the 2 groups (3 in each
group).
Discussion
To the best of our knowledge, the present study is the first
randomized trial assessing the effects of CABG 
Change in WMIS byEchocardiography Indexes After Surgery (x  s)Table 3 Change in WMIS byEchocardiography Indexes After Surgery (x  s)
CABG  BMMNC
Group
(n  31)
Placebo-Control
Group
(n  28) p Value
WMIS change* 6 (8,3) 2.5 (6.75, 0.00) 0.025
WMIS change in segment with
abnormal movement
2.5 (8,4) 3 (6.00,0.25) 0.011
Values are median (quartile). *WMIS changing  sum of WMSIpre-operative  sum of WMSIpost-
perative.
WMIS  wall motion index score; other abbreviations as in Table 1.
Change in SPECT Indices After Surgery (x  s)Table 4 Change in SPECT Indices After Surgery (x  s)
CABG  BMMNC
Group
(n  31)
Placebo-Control
Group
(n  28) p Value
Pre-operative ratio
of filling defect, %
26 (20, 33) 22 (17.5, 27.0) 0.158
Post-operative ratio
of filling defect, %
24 (10, 34) 20 (9.5, 34.5) 0.624
Change in value* 0.5 (3.0, 7.5) 1 (4.0, 6.5) 0.826
Values are median (quartile). *Change in value  filling defect ratiopre-operative  filling defect
atio(6 months after surgery).
Abbreviations as in Table 1.BMMNCs in patients with PMI complicated by chronic
heart failure. It showed that BMMNCs when added to
CABG improve LVEF 6 months after CABG, and the
score in segments with abnormal motion decreased signif-
icantly. The distance of the 6MWT improved more signif-
icantly in the CABG  BMMNC group than in the
placebo-control group, and serum BNP in the CABG 
BMMNC group decreased significantly compared with that
in the placebo-control group. All these results indicate that
BMMNCs can improve heart function in patients with
PMI complicated by chronic heart failure in the short term
and might have a positive impact on long-term prognosis
and exercise tolerance. The findings of this study add
important new evidence to the current debate regarding the
value of stem cell therapy for heart failure after MI (6,7,10).
BMMNCs are an ideal cell resource for cell therapy.
Previous studies have demonstrated that autologous BMMNCs
have the potential to improve heart function by inducing
angiogenesis and myocardial regeneration (8,11–13). There
are several important subclasses of BMMNCs, such as
endothelial progenitor cells, mesenchymal stem cells, and
hemopoietic progenitor cells; each type may be capable of
improving heart function. Moreover, BMMNCs are easily
harvested, and the biological characteristics are largely
unaffected when isolated. In our study, in vitro cultured
BMMNCs showed good proliferation. No patients had
malignant arrhythmia in the present study, indicating that
BMMNCs without isolating culture are safe for clinical use.
Traditionally, stem cells are delivered intramyocardially,
mostly around the infarcted area, during surgery (2). Al-
though a large number of transplanted cells will stay in situ
via the intramyocardial route, a compromised survival rate
and impaired proliferation ability are expected when a large
number of cells stay in an ischemic or infarcted area.
Moreover, the intramyocardially delivered cells are unevenly
Results of 6-Min Walking Test (x  s)Table 5 Results of 6-Min Walking Test (x  s)
CABG  BMMNC
Group
(n  30)
Placebo-Control
Group
(n  27) p Value
Pre-operative distance, m 466 (402, 495) 448 (383, 497) 0.467
Distance after 6 months, m 500 (472, 529) 470 (416, 501) 0.009
Distance change* 45 (13, 68) 10 (30, 54) 0.042
Values are median (quartile). *Distance change  distancepre-operative  distance(6 months after
urgery).
Abbreviations as in Table 1.
BNP Value Before and After Surgery (x  s)Table 6 BNP Value Before and After Surgery (x  s)
CABG  BMMNC
Group
(n  31)
Placebo-Control
Group
(n  28) p Value
Pre-operative, fmol/l 1,329 (704, 1,653) 862 (680, 1,646) 0.439
Post-operative, fmol/l 760 (602, 996) 938 (689, 1,358) 0.129
Change in value* 476 (23, 727) 34 (270, 509) 0.034Values are median (quartile). *Change in value  BNPpre-operative BNP(6 months after surgery).
Abbreviations as in Table 1.
2415JACC Vol. 57, No. 24, 2011 Hu et al.
June 14, 2011:2409–15 Stem Cells in Post-Infarction Heart Failuredistributed, and some parts where cell therapy is needed are
unreachable (14). A previous study revealed that, when
delivered via a coronary artery in an arrested heart, a high
percentage of transplanted cells will remain within the
myocardium of a patient with a PMI (14). In the current
study, stem cells were delivered via a graft in an arrested
heart. Possibly, abundant lateral branches will enable an
even distribution of intragraft-delivered stem cells. More-
over, we hypothesize that, in an arrested heart, capillaries
are dilated and vessel permeability is increased so that
transplanted cells adhering to the vessel wall will easily
migrate to the myocardium. In the present study, the aorta
was declamped 5 min after cell injection. This protocol
might prolong the contact time between BMMNCs and a
microcoronary artery, enhance the adhering ability of
BMMNCs, and consequently decrease the number of
BMMNCs washed out of the heart (15).
Compared with other studies of CABG combined with
stem cell therapy (11,12), the current study controlled
patient selection rigorously to only include those with
triple-vessel disease, PMI, and chronic heart failure. More-
over, the candidates were not eligible for this study unless
they underwent isolated CABG (refers to those receiving
CABG only). Also, we took great care to control confound-
ing factors arising from surgery, such as the type of CABG
techniques and the surgeons.
Study limitations. This study is, however, not without its
limitations. The number of patients involved is still small
and compared with positron emission tomography/
computed tomography, the resolution of SPECT imaging
used in our study was relatively low, which could lead to
false-negative findings. We did find the that imaging in
parts of patients was unclear, and analysis was almost
impossible. Moreover, our current Siemens scanner could
not provide accurate quantitative data about infarction size.
Our study was designed to focus on the effects of stem cells
effects on global heart function instead of MI size.
Conclusions
In summary, patients with PMI and chronic heart failure
could potentially benefit from isolated CABG combined
with BMMNCs delivered via a graft vessel. The LVESVI
decreased, LVEF increased, and the exercise tolerance
improved during follow-up. Further large randomized trials
are needed to assess the effects of BMMNCs on the
long-term prognosis of patients using more clinically mean-
ingful outcomes.
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